Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Carcinoma, Hepatocellular 28Breast Neoplasms 26Small Cell Lung Carcinoma 20Lung Neoplasms 20Triple Negative Breast Neoplasms 18Urinary Bladder Neoplasms 17Neoplasms 16Carcinoma, Transitional Cell 16Neoplasm Metastasis 15Melanoma 15Colorectal Neoplasms 15Uterine Cervical Neoplasms 11Carcinoma, Renal Cell 10Stomach Neoplasms 7Recurrence 7Head and Neck Neoplasms 7Prostatic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma, Malignant 5Liver Neoplasms 5Carcinoma, Squamous Cell 5Ovarian Neoplasms 4Esophageal Neoplasms 4Carcinoma, Merkel Cell 4Biliary Tract Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Thoracic Neoplasms 3

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Rare Malignant Solid Neoplasm × atezolizumab × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡